Biologics and small molecules treatment for moderate-to-severe atopic dermatitis patients with comorbid conditions and special populations: an Italian perspective
This comprehensive review offers a detailed look at atopic dermatitis (AD) treatment in Italy, focusing primarily on the use of biologics and small molecules. In response to advancing knowledge of AD's causes and treatments, there's a global need for updated guidelines to provide physicia...
| Main Authors: | , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
PAGEPress Publications
2023-09-01
|
| Series: | Dermatology Reports |
| Subjects: | |
| Online Access: | https://www.pagepress.org/journals/index.php/dr/article/view/9839 |
| _version_ | 1797687118317748224 |
|---|---|
| author | Alba Guglielmo Maria Ludovica Deotto Luigi Naldi Giuseppe Stinco Alessandro Pileri Bianca Maria Piraccini Anna Belloni Fortina Andrea Sechi |
| author_facet | Alba Guglielmo Maria Ludovica Deotto Luigi Naldi Giuseppe Stinco Alessandro Pileri Bianca Maria Piraccini Anna Belloni Fortina Andrea Sechi |
| author_sort | Alba Guglielmo |
| collection | DOAJ |
| description |
This comprehensive review offers a detailed look at atopic dermatitis (AD) treatment in Italy, focusing primarily on the use of biologics and small molecules. In response to advancing knowledge of AD's causes and treatments, there's a global need for updated guidelines to provide physicians with a more comprehensive clinical perspective, facilitating personalized treatment strategies. Dupilumab, a groundbreaking biologic, gained approval as a significant milestone. Clinical trials demonstrated its ability to significantly reduce AD severity scores, with an impressive 37% of patients achieving clear or nearly clear skin within just 16 weeks of treatment. Real-world studies further support its efficacy across various age groups, including the elderly, with a safety profile akin to that of younger adults. Tralokinumab, a more recent approval, shows promise in clinical trials, particularly among younger populations. However, its real-world application, especially in older individuals, lacks comprehensive data. JAK inhibitors like Upadacitinib, baricitinib, and abrocitinib hold substantial potential for AD treatment. Nevertheless, data remains limited for patients over 75, with older adults perceived to carry a higher risk profile. Integrated safety analyses revealed individuals aged 60 and above experiencing major adverse cardiovascular events and malignancies, underscoring the need for cautious consideration. While these therapies offer promise, especially among younger patients, further research is essential to determine their safety and efficacy in various populations, including pediatric, geriatric, and those with comorbidities. This review highlights the evolving landscape of AD treatment, with biologics and small molecules emerging as potent tools to enhance the quality of life for AD-affected individuals.
|
| first_indexed | 2024-03-12T01:14:38Z |
| format | Article |
| id | doaj.art-6502020d10754ad5a94a2e70ed7b04f5 |
| institution | Directory Open Access Journal |
| issn | 2036-7392 2036-7406 |
| language | English |
| last_indexed | 2024-03-12T01:14:38Z |
| publishDate | 2023-09-01 |
| publisher | PAGEPress Publications |
| record_format | Article |
| series | Dermatology Reports |
| spelling | doaj.art-6502020d10754ad5a94a2e70ed7b04f52023-09-13T18:25:51ZengPAGEPress PublicationsDermatology Reports2036-73922036-74062023-09-0110.4081/dr.2023.9839Biologics and small molecules treatment for moderate-to-severe atopic dermatitis patients with comorbid conditions and special populations: an Italian perspectiveAlba Guglielmo0Maria Ludovica Deotto 1Luigi Naldi 2Giuseppe Stinco3Alessandro Pileri4Bianca Maria Piraccini5Anna Belloni Fortina6Andrea Sechi7Dermatology Unit, IRCCS Azienda Ospedaliero-Universitaria di Bologna, Policlinico S. Orsola-Malpighi, Bologna; Institute of Dermatology, Azienda Sanitaria Universitaria Friuli Centrale (ASUFC), UdineDermatology Unit, Department of Medicine DIMED, University of Padova, PadovaDermatology Unit, San Bortolo Hospital, VicenzaInstitute of Dermatology, Azienda Sanitaria Universitaria Friuli Centrale (ASUFC), Udine; Department of Medicine (DAME), University of Udine, UdineDermatology Unit, IRCCS Azienda Ospedaliero-Universitaria di Bologna, Policlinico S. Orsola-Malpighi, BolognaDermatology Unit, IRCCS Azienda Ospedaliero-Universitaria di Bologna, Policlinico S. Orsola-Malpighi, BolognaDermatology Unit, Department of Medicine DIMED, University of Padova, PadovaDermatology Unit, San Bortolo Hospital, Vicenza This comprehensive review offers a detailed look at atopic dermatitis (AD) treatment in Italy, focusing primarily on the use of biologics and small molecules. In response to advancing knowledge of AD's causes and treatments, there's a global need for updated guidelines to provide physicians with a more comprehensive clinical perspective, facilitating personalized treatment strategies. Dupilumab, a groundbreaking biologic, gained approval as a significant milestone. Clinical trials demonstrated its ability to significantly reduce AD severity scores, with an impressive 37% of patients achieving clear or nearly clear skin within just 16 weeks of treatment. Real-world studies further support its efficacy across various age groups, including the elderly, with a safety profile akin to that of younger adults. Tralokinumab, a more recent approval, shows promise in clinical trials, particularly among younger populations. However, its real-world application, especially in older individuals, lacks comprehensive data. JAK inhibitors like Upadacitinib, baricitinib, and abrocitinib hold substantial potential for AD treatment. Nevertheless, data remains limited for patients over 75, with older adults perceived to carry a higher risk profile. Integrated safety analyses revealed individuals aged 60 and above experiencing major adverse cardiovascular events and malignancies, underscoring the need for cautious consideration. While these therapies offer promise, especially among younger patients, further research is essential to determine their safety and efficacy in various populations, including pediatric, geriatric, and those with comorbidities. This review highlights the evolving landscape of AD treatment, with biologics and small molecules emerging as potent tools to enhance the quality of life for AD-affected individuals. https://www.pagepress.org/journals/index.php/dr/article/view/9839Atopic dermatitisbiologicanti-interleukinsmall-moleculesJAK inhibitors |
| spellingShingle | Alba Guglielmo Maria Ludovica Deotto Luigi Naldi Giuseppe Stinco Alessandro Pileri Bianca Maria Piraccini Anna Belloni Fortina Andrea Sechi Biologics and small molecules treatment for moderate-to-severe atopic dermatitis patients with comorbid conditions and special populations: an Italian perspective Dermatology Reports Atopic dermatitis biologic anti-interleukin small-molecules JAK inhibitors |
| title | Biologics and small molecules treatment for moderate-to-severe atopic dermatitis patients with comorbid conditions and special populations: an Italian perspective |
| title_full | Biologics and small molecules treatment for moderate-to-severe atopic dermatitis patients with comorbid conditions and special populations: an Italian perspective |
| title_fullStr | Biologics and small molecules treatment for moderate-to-severe atopic dermatitis patients with comorbid conditions and special populations: an Italian perspective |
| title_full_unstemmed | Biologics and small molecules treatment for moderate-to-severe atopic dermatitis patients with comorbid conditions and special populations: an Italian perspective |
| title_short | Biologics and small molecules treatment for moderate-to-severe atopic dermatitis patients with comorbid conditions and special populations: an Italian perspective |
| title_sort | biologics and small molecules treatment for moderate to severe atopic dermatitis patients with comorbid conditions and special populations an italian perspective |
| topic | Atopic dermatitis biologic anti-interleukin small-molecules JAK inhibitors |
| url | https://www.pagepress.org/journals/index.php/dr/article/view/9839 |
| work_keys_str_mv | AT albaguglielmo biologicsandsmallmoleculestreatmentformoderatetosevereatopicdermatitispatientswithcomorbidconditionsandspecialpopulationsanitalianperspective AT marialudovicadeotto biologicsandsmallmoleculestreatmentformoderatetosevereatopicdermatitispatientswithcomorbidconditionsandspecialpopulationsanitalianperspective AT luiginaldi biologicsandsmallmoleculestreatmentformoderatetosevereatopicdermatitispatientswithcomorbidconditionsandspecialpopulationsanitalianperspective AT giuseppestinco biologicsandsmallmoleculestreatmentformoderatetosevereatopicdermatitispatientswithcomorbidconditionsandspecialpopulationsanitalianperspective AT alessandropileri biologicsandsmallmoleculestreatmentformoderatetosevereatopicdermatitispatientswithcomorbidconditionsandspecialpopulationsanitalianperspective AT biancamariapiraccini biologicsandsmallmoleculestreatmentformoderatetosevereatopicdermatitispatientswithcomorbidconditionsandspecialpopulationsanitalianperspective AT annabellonifortina biologicsandsmallmoleculestreatmentformoderatetosevereatopicdermatitispatientswithcomorbidconditionsandspecialpopulationsanitalianperspective AT andreasechi biologicsandsmallmoleculestreatmentformoderatetosevereatopicdermatitispatientswithcomorbidconditionsandspecialpopulationsanitalianperspective |